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© The AuthContinuous-flow processing in the manufacturing of modern biotherapeutics represents a great potential and could signifi-
cantly improve productivity and product quality as well as reduce operating costs. Microfluidic perfusion systems are not
only capable for producing therapeutic proteins but also suitable for organ-on-a-chip based drug testing and toxicology
studies. Integrating modular unit operations for protein purification in the microfluidic cell culture device can lead to point-
of-care therapeutic protein production. The multi-organ microfluidic platforms that integrate several organ-on-a-chip micro-
fluidic units will help in preclinical testing of drug substances and toxicological studies by producing highly reliable
preclinical pharmacokinetic data. In this perspective, the current state of the art and future trends of continuous flow
systems are summarized for biopharmaceutical production and organ-on-a-chip drug testing.
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In the past decades, the sales of biotherapeutics, including
monoclonal antibodies, grew rapidly and biologics became the
dominant product class in the pharmaceutical market [1–3].
Based on the prognosis, the global worldwide sales of approved
monoclonal antibodies, the largest product type of biologics, was
estimated to reach approximately $125 billion by the year 2020
[4]. The current rapidly changing market environment and the
growing competition induced by biosimilars push the biopharma-
ceutical companies increasingly into developing innovative,
highly flexible, and cost-effective manufacturing processes [5].
Process intensification through conversion from batch-based
production to continuous manufacturing has been applied effec-
tively by the pharmaceutical industry for small molecule drugs.
Continuous applications for biologics manufacturing on the other
hand have their limitations due to the complexity of automation
and validation challenges. For the time being, the biopharmaceu-
tical industry predominantly employs batch processes for recom-
binant protein manufacturing, whereas only less than 10% of the
approved biologics are produced through continuous (or perfu-
sion) processing [6]. Recently, the field of continuous bioproces-
sing is gaining greater acceptance and there is a growing interest
to realize the benefits of continuous biomanufacturing [7]. The
paradigm shift in biologics production from batch to continuous
bioprocessing technology can result in significant benefits from
standardizing on common terminology, as well as from the align-
ment of expectations and goals. It is easier to implement process
standardization in a continuous process, so all biological drugs
could be manufactured in a common manner. Full process stan-
dardization can be realized throughout the different phases of
manufacturing process (e.g., process development, clinical pro-
duction, commercial manufacturing) with identical equipment
and control systems. Processes standardization also help the regu-
latory approval of biologics [8]. The US Food and Drug Admin-
istration (FDA) is encouraging manufacturers to switch to these
newer and more efficient continuous processes that can enable
faster production and more reliable products [9].
Flow processing in monoclonal antibody production has simi-
lar yield and purity compared to batch processing but withcorrespondence: guttman@mik.uni-pannon.hu
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or(s). This article is published with Open Access at www.akademiai.cincreased productivity and much smaller manufacturing footprint
[8]. Continuous manufacturing of recombinant therapeutic pro-
teins offers several advantages over batch processing: improved
and consistent product quality, reduced equipment size, stream-
lined processes, low process cycle times, reduced capital and op-
erating cost, increased flexibility, high volumetric productivity,
higher level of automation and consequently less human interac-
tion, an increased use of single-use equipment, and reduced in-
ventory and storage needs [10].
Flow process development is focused on strategies to mini-
mize intermediate sample purification to ensure a continuous
stream of material between different unit operations. This ap-
proach also requires better process knowledge, equipment, and
technological advances. Successful adaption of continuous pro-
cessing by the industry requires the integration of process com-
ponents involved in the manufacturing [11]. Product titer and cell
productivity increase, improved intensification, smaller equipment
size, maximum capacity utilization, and smaller processing lots
show a trend towards the prevalent application of integrated con-
tinuous processing [12].
The newest developments in tissue engineering, biomaterials,
and microfabrication methods enabled the construction of bio-
logically relevant models of human organs on a chip. The so-
called continuous perfusion organ-on-a-chip systems can help to
speed up drug discovery and improve disease modeling. It may
also facilitate drug testing by producing more reliable preclinical
pharmacokinetic and pharmacodynamic data [13].
2. Batch vs. Flow-Based Production of Biotherapeutics
Therapeutic antibodies are mainly produced in mammalian
host cell lines such as Chinese hamster ovary (CHO) and murine
myeloma cells (NS0). The selection of expression system is
based on its productivity with acceptable product quality attri-
butes [14].
The cell culture processes for therapeutic protein production
can follow three different types. The simplest mammalian cell
culture process is a batch process. This is a closed system where
all nutrients are added into the medium that are necessary for cell
growth and production of proteins prior to addition of the cells.
In the case of fed-batch process, a concentrated form of the initial
culture medium is used for feeding. The feeding solutionom
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L. Hajba and A. Guttmancomposition can be varied, based on the metabolic state of the
cells at different culture phases. Continuous cell culturing has
two options. In the case of chemostat cultures, fresh medium is
continuously added to the bioreactor and the fermented medium
is removed containing leftover nutrients, waste metabolites, prod-
uct, and even viable cells at a constant flow rate to keep the cul-
ture volume unchanged. Perfusion culturing, on the other hand,
retains the cells in the bioreactor to avoid loss of viable cells.
[15]. Maximum cell densities are 1–2 × 106 cells/mL, 8–12 ×
106 cells/mL, and 10–30 × 106 cells/mL for batch, fed-batch, and
perfusion culturing, respectively [16]. The schemes of typical
growth, cell viability, and mAbs production of the different pro-
cesses are depicted in Figure 1.
In perfusion mode, there are different ways to keep the cells in
culture, while removing the spent media. One way relies on filtra-
tion systems that keep the cells in the bioreactor by using internal
filters, external loop flow-through filters, and centrifugation. Other
methods for perfusion involve immobilization of the host cells on
a solid support [11] such as microcarrier particles, magnetic
microbeads, hollow capillary fibers, flat plates, fibrous matrices
[17, 18], supermacroporous cryogel [19, 20], and membranes,
which are retained or fixed in the bioreactor.
Perfusion manufacturing processes have the following advan-
tages compared to the fed-batch processes: higher productivity,
more consistent product profile, and smaller production footprint
[21, 22]. Furthermore, if the product molecule is thermally insta-
ble, the product can be continuously removed during the perfu-
sion process from the high-temperature bioreactor environments
[21]. In the frame of quality by design (QbD) approach, perfu-
sion production process can be planned and implemented effi-
ciently and cost effectively [21, 23]. Continuous perfusion
technology allows significant decrease in the residence time of
the molecule in the bioreactor, which has benefits in the produc-
tion of therapeutic proteins (e.g., mAbs). Modifications, such as
post-secretion glycosylation changes and deamidation are mini-
mized with continuous cultivations; therefore, it results in uncom-
promised product quality as well as less modified and more
consistent glycoform profiles [12, 24, 25]. Yang et al. showed
that continuous perfusion culture can improve the product quality
by producing more active protein species (64.3%) compared to
conventional fed-batch process (54.1%) [22]. Willard et al. made
a comparison of the different culturing processes, namely, batch,Figure 1. Overview of different operation types with their cell viability and pfed-batch, and perfusion in the production of mAbs. They used
two types of perfusion setups. One was equipped with an alter-
nating tangential-flow (ATF) filtration device, which used hol-
low-fiber filters to retain the cells. The second one used a
packed bed bioreactor, in which the cells were immobilized
on a solid support. With the ATF perfusion process, they
achieved noteworthy high cell density of 7.4 × 107 cells/mL,
producing 11.4 g of antibody within 2 weeks. That represents
12-fold and 2.5-fold increases of product output compared with
the batch and fed-batch processes, respectively [26]. Xu et al.
compared the different production processes for mAb
manufacturing. They concluded that perfusion cultures had the
highest productivity (2.29 g/L/day) due to the high cell density
maintained compared to the fed-batch cultures (0.39–0.49 g/L/day)
[27]. An often observed disadvantage of perfusion processes is the
high media cost involved, since continuous media exchange is re-
quired to maintain the desired high viable cell density. They
proved that media cost for high productivity perfusion cultures
could actually be lower than in the fed-batch process because of
the low cell specific perfusion rates (14 ± 1 pL/cell/day) used in
the continuous perfusion process [27]. These case studies also
showed that perfusion production systems are getting more popu-
lar and economically feasible in biomanufacturing of mAbs.
3. Continuous-Flow Production of Monoclonal Antibodies in
Microfluidics Systems
Culturing adherent mammalian cells in a microfluidic perfu-
sion bioreactor system allows control over the microenvironment
of the cells, regulating cell–cell and cell–matrix interactions, nu-
trient supply, removal of product, and waste product biomole-
cules, which all have effects on cell growth, viability, and
metabolism. The highly controlled microenvironments are not
available in static cultures, where concentrations of nutrients,
product, and waste products are changing over time. Designing
and operating a microfluidic perfusion system for cell culture
are rather difficult and come with many challenges. Kim et al.
summarized the guiding principles to implement a microfluidic
perfusion culture system, and the essential design and opera-
tional issues are summarized in Figure 2 [28].
Several research groups studied long-term culturing of adherent
cells in microfluidic bioreactors for mAbs production [29–31].roduct production over time during a typical mAb production processes
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Figure 2. Guiding principles and technical issues for the robust operation of a microfluidic perfusion culture system. Reproduced with permission
from Ref. [28]
Continuous-Flow-Based Microfluidic SystemsThey used different types of cell adhesion agents such as fibronec-
tin [30] and poly-D-lysine [31] to improve the adhesion and viabil-
ity. Green et al. tested the effect of different microchannel
geometries and thicknesses, as well as the influence of flow rate
[29]. Their results demonstrated that these parameters had great in-
fluence in cell adhesion and growth. Garza-Garcia et al. tested a fi-
bronectin-coated microfluidic device with zigzag channel (length =
44 mm) for the production of Infliximab (Remicade) [32]. The sin-
gle microfluidic bioreactor produced 14.4 μg of mAb in 24 h at a
flow rate of 5 μL/min. The outlet concentration was 2 mg/L at res-
idence times of 0.42 min. The productivity of the continuous flow
microfluidic bioreactor was more than three orders of magnitude
higher compared to fed-batch processes. Alvarez and coworkers
further optimized the geometry of the microfluidic device for
mAbs production [30]. The most efficient configuration was the
use of a series of donut-shaped reservoirs, which yielded mAb
concentrations of 7.2 mg/L at residence times lower than 1 min.
Perez-Pinera et al. developed a portable, fully integrated, and
closed microbioreactor platform for programmable production of
biologics shown in Figure 3 [33]. As a proof of principle, they
produced interferon-α2b (IFNα2b) and recombinant human
growth hormone (rhGH) using a Pichia pastoris strain
255B cells. The microbioreactor produced 19.73 ± 0.72 μg
IFNα2b and 43.7 ± 6.3 μg rhGH in 20 h, respectively. Integrat-
ing the system in a modular microfluidics setting for protein puri-
fication can advance the treatment of human diseases in the
point-of-care fashion [34].Figure 3. The principal components of a microbioreactor for pro-
grammable production of biologics. Reproduced with permission from
Ref. [33]
120Besides the cell culturing methods, cell-free protein synthesis
(CFPS) is one of the widely used methods for the production of
therapeutic proteins. CFPS method reduces the production time of
proteins to a few hours compared to production systems in cells,
which typically takes days and sometimes even weeks [35, 36].
CFPS uses cell extracts containing the biological machinery
(DNA for encoding a specific gene and additional metabolites)
necessary for in vitro protein production. Current trend applies
CFPS in continuous microfluidic-based bioreactors [37]. The ser-
pentine channel microfluidic bioreactors developed by Timm
et al. shown in Figure 4 found their way in applications requiring
the on-demand synthesis and subsequent purification of protein
therapeutics [38]. Compared to conventional batch reactions, the
average yield increased by nearly 40% with the microfluidic bio-
reactor. The developed microdevice represented a significant step
toward rapid production of biotherapeutics, even at the point-of-
care if necessary.
4. The Organ-on-a-chip Concept for Drug Testing
Organ-on-a-chips are continuously perfused microfluidic de-
vices for culturing living cells to model physiological functions
of tissues and organs such as skin, liver, kidney, etc. The sim-
plest system contains only one kind of cell (e.g., kidney tubular
epithelial cells) in the perfused microfluidic chamber that ex-
hibits functions of one tissue type. In complex organ-on-a-chip
microfluidic systems, porous membranes are installed between
two or more microchannels, lined up on opposite sides by dif-
ferent cell types, to recreate interfaces between different tissues
such as lung alveolar–capillary interface as described inFigure 4. Serpentine channel microfluidic bioreactor design for cell-
free production of biotherapeutics. Reproduced with permission from
Ref. [38]
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L. Hajba and A. GuttmanRef. [39]. Advanced 3D tissue engineered constructs are ap-
plied more frequently instead of two dimensional (2D) cell cul-
ture to better mimic the complex three dimensional (3D)
in vivo microenvironment of an organ, where the cells and the
extracellular matrix (ECM) exist in a well-defined structure.
3D cell culture organ-on-a-chip systems can provide a better
platform for preclinical testing of drug substances [40, 41].
These systems can be perfused to create dynamic culture envi-
ronments and can be exposed to concentration gradients of
drugs at the same time to perform drug metabolism and toxi-
cology studies (Figure 5) [42, 43].
Bioprinting as an extension of 3D printing offers the ability
to create a 3D biomimetic tissue by depositing cells and, in
some cases, multiple cell types into a 3D construct with pre-
cise and reproducible spatial distribution. Applying bioprint-
ing, organ-on-a-chip with 3D biomimetic tissues can be
created and with continuous perfusion the tissues can be sup-
plied with nutrients and growth factors and the metabolism
products can be removed. Nowadays, bioprinters and bioprint-
ing services are commercially available (e.g., www.biobots.io,
www.organovo.com) [44]. Precise cell/ECM positioning and
creation of complex biological structures are possible with the
3D printing technologies such as micro-extrusion, inkjet, and
laser-assisted printing. 3D bioprinting accurately controls the
spatial distribution and layer-by-layer assembly of cells,Figure 5. Concept behind the organ-on-a-chip modules for drug metabolism
Figure 6. Advantages of microfluidic models over conventional in vitro andECMs, and other biomaterials. Organ-on-a-chip with heteroge-
neity, proper 3D cellular arrangement, and tissue-specific
functions can all be produced [45]. Wevers et al. developed
an OrganoPlateW microfluidic platform for culturing three-
dimensional networks of active neurons and supporting glial
cells. This novel microfabricated device can help in the develop-
ment and testing of new drug candidates for brain diseases, and
it is a promising tool for in vitro brain modeling [46].
Microfluidic models of organs allow real-time and non-invasive
monitoring of cell-based assays with tissue- and organ-level
complex physiological processes that are especially useful in
cancer research. Microfluidic models have several advantages
over in vitro and in vivo models as listed in Figure 6, but the
main advantage is the high human relevance and precision that
cannot be achieved with conventional methods. [47].
Microfluidic devices provide great opportunities in cancer biol-
ogy and clinical oncology research, as well as high-throughput
drug screening. With their help, multiparameter studies on iso-
lated single cancer cells that are useful for clinical and diagnostic
laboratories can be performed. Furthermore, reconstruction of the
cancer microenvironment with microfluidic perfusion system can
support clinical diagnostic and drug testing [48].
Loskill et al. developed a Lego-like plug and play system re-
ferred to as μOrgano, which enabled to create integrated multi-
organ microphysiological systems with the connection of a singleand toxicology studies. Reproduced with permission from Ref. [42]
in vivo models. Reproduced with permission from Ref. [47]
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Continuous-Flow-Based Microfluidic Systemsorgan on a chip module. The plug and play μOrgano system has
the following features: (1) separate loading of different cell types;
(2) temporal control of individual cell cultures for differentiation
and tissue development; and (3) subsequent temporal control of
fluidic connections of the individual tissues [49].
Maschmeyer et al. developed a four-organ microfluidic plat-
form for absorption, distribution, metabolism, and excretion
(ADME) profiling and toxicity testing of drug candidates as
shown in Figure 7 [50]. The four-organ-chip with the combina-
tion of a human skin, intestine, liver, and kidney model enabled
the study of absorption and distribution of the drug molecules be-
tween the model organs and the first path metabolism in the liver
tissue, secondary metabolism, and, finally, excretion through the
kidney model. The developed microfluidic platform can help to
obtain more reliable pharmacokinetic and pharmacodynamic data,
such as effective concentration as well as intensity of therapeutic
and adverse effects.
The micro cell culture analog (μCCA) device is a multi-organ-
chip microfluidic system with the challenging goal to create a
model for the entire human body. First of all, for wider accep-
tance of this technology, the drug test results obtained with
μCCAs with animal cell lines should be compared and validated
with the animal studies. Human μCCAs (operated with human
cell lines) data should also be compared considering clinical effi-
cacy and toxicity data [51].
5. Conclusions and Future Prospective
Utilization of continuous processing in the manufacturing of
modern biotherapeutics could significantly improve productivity
and throughput, and result in improved and consistent product
quality at a reduced capital and operating cost. Productivity could
be further increased with the application of microfluidic perfusion
bioreactors. Cell viability and growth and, thus, the production of
biologics can still be improved with optimization of channel ge-
ometry, thickness, and flow rate. Recently introduced bioprinting
opens up new horizons to create more advanced 3D culture
microfluidic devices for biologics production. Integrating modu-
lar unit operations for protein purification in the microfluidic cell
culture device can lead to point-of-care therapeutic protein pro-
duction. Cell-free protein synthesis method drastically reduces
protein production times, i.e., to a few hours compared to cell
culturing system, where it takes typically several days. Microflui-
dic perfusion devices in a form of organ-on-a-chips can culture
living cells to model physiological functions of tissues and or-
gans such as skin, liver, or kidney. These microfluidic devices
with different organ functionalities can be integrated into oneFigure 7. Four-organ-chip microfluidic platform. Numbers represent
the four tissue culture compartments for intestine (1), liver (2), skin (3),
and kidney (4) tissue. Reproduced with permission from Ref. [50]
122microfluidic system to model the relevant parts of the human
body. However, several issues should be addressed in the fu-
ture for an organ-on-a-chip microfluidic system. One is that the
organ-on-a-chip must authenticly replicate the in vivo cellular
behavior [51]; thus, several process parameters (e.g., culturing
media, temperature, flow velocity, channel geometry) should
be optimized. Another one is the integration of several organ-
on-a-chip devices into one combined microfluidic system to
produce a bubble free integrated platform. This latter is still
challenging, and each integration method (e.g., microfluidic
chamber connection with tubing, all chamber integration into
one single chip) should be checked individually. Finally, using
such an integrated platform, universal culture media are neces-
sary for the different cell types [52]. These multi-organ micro-
fluidic platforms will help in preclinical testing of drug
substances and toxicological studies by producing more reli-
able preclinical pharmacokinetic and pharmacodynamic data.
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